It marks the first of seven peptide drugs the FDA's Pharmacy Compounding Advisory Committee will address on Thursday and Friday.

Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple ...

Roche’s Vabysmo disappointed investors again. In the second quarter, the eye drug’s sales of about 1.04 billion Swiss francs ($1.27 billion) missed analysts’ expectations by 7.1%. | On an investor ...

In a landmark moment for its oncology ambitions, GSK has secured FDA approval for Jideytro (zidesamtinib) as the first ...

While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the ...

The FDA has called out Sanofi’s promotion of respiratory syncytial virus (RSV) antibody Beyfortus in a new untitled letter, ...

A U.K. marketing watchdog has reprimanded Sanofi for using “a highly misleading interpretation of data” to make disparaging ...

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become the first drug to specifically ...

Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...

Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has ...

Novo Nordisk has accused Eli Lilly of running ad campaigns containing “deliberately false” messages that mislead the public ...

Detailed phase 3 results suggest the two-drug combination of Gilead Sciences’ lenacapavir and Merck & Co.’s islatravir has ...